SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding
SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated …

… Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19 …
to mAbs by SARS-CoV-2, we reviewed the available in vitro neutralization data for mAbs …

… of COVID-19 therapeutic antibodies against a clinical strain of the Omicron variant. The panel
consists of therapeutic antibodies that … Within this panel, all antibodies retained neutralizing …

… used to assess the extent to which antibodies are able to neutralize SARS-CoV-2 in vitro.
Serum or plasma samples from any species, as well as monoclonal antibodies (mAbs), can be …

… potent in vitro neutralizing RBD and NTD antibodies as well as in vitro infection-enhancing
RBD and NTD antibodies from individuals infected with SARS-CoV-1 or SARS-CoV-2. …

… antibody may be needed to treat COVID-19 patients infected with the United Kingdom variant
compared to patients with wildtype virus… , therapeutic antibodies to treat COVID-19 patients …

… Our data also confirm that the SARS-CoV-2 neutralizing antibodies acquired during infection
target almost entirely the NTD and the RBD. In the RBD, the possibility to escape is limited …

… For the main objective of this review, all original studies reporting on the sensitivity and/or
specificity of antibodies against SARS-CoV-2 were included in the analysis. More than 20,000 …

… antibodies with neutralizing activity against SARS-CoV-2. … for SARS-CoV-2 infection and
associated COVID-19 disease. … to reduce SARS-CoV-2 infection and a handful of monoclonal …

… of activity of therapeutic antibodies currently licensed in the … BA.2 and BA.5 variants, we
compared the neutralising power of monoclonal antibodies against the Omicron BA.1, BA.2 and …